Send the following on WhatsApp
Continue to ChatAccording to the NCI website Alectinib is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the … https://oncoletter.ch/krebstherapie/alle-wirkstoffe/wirkstoff/alectinib-alecensa-r.html